Clinical Trials
36 trialsTesting the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Curis, Inc.
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
BOSon
Massachusetts General Hospital
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Huazhong University of Science and Technology
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Canadian Cancer Trials Group
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
ZEBRA
Massachusetts General Hospital
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Baptist Health South Florida
BRAZAN
Dana-Farber Cancer Institute
Epco, Zanu, Ritux for R/R FL or MZL
Dana-Farber Cancer Institute
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
GLOASIS
The Lymphoma Academic Research Organisation
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
H. Lee Moffitt Cancer Center and Research Institute
FIL_MOZART
Fondazione Italiana Linfomi - ETS
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Virginia Commonwealth University
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
M.D. Anderson Cancer Center
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Sun Yat-sen University
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Ruijin Hospital
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Dana-Farber Cancer Institute
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
SWOG Cancer Research Network
Benefit VA
VA Office of Research and Development
Pola-ZR2P in Previously Untreated DLBCL
Navy General Hospital, Beijing
Zanubrutinib Combined With G-CVP in Previously Untreated FL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ZEBRA
University College, London
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PETHEMA Foundation
R-ICE+X
Ruijin Hospital
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Navy General Hospital, Beijing
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Fudan University
ZBR
Institute of Hematology & Blood Diseases Hospital, China
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Chinese PLA General Hospital
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Ruijin Hospital